What adverse effect should be monitored when using an ipratropium inhaler?

Ipratropium is an anticholinergic medication commonly used as an inhaler for managing symptoms of chronic obstructive pulmonary disease (COPD) and asthma. One of the primary adverse effects associated with anticholinergic medications, including ipratropium, is xerostomia, or dry mouth. This occurs because anticholinergics inhibit the action of acetylcholine, leading to reduced secretions in various glands, including salivary glands.

Patients using an ipratropium inhaler may experience this side effect, which can be uncomfortable and impact the quality of life. Monitoring for xerostomia allows healthcare providers to address this symptom promptly, potentially offering solutions such as oral moisturizers or sugar-free gums to alleviate discomfort and help maintain oral hygiene.

While nausea, headache, and insomnia can be potential side effects of various medications, they are less commonly associated with ipratropium specifically. Xerostomia is the most characteristic and notable adverse effect to monitor for with this particular inhaler.